Daewoong Pharma to build third botulinum toxin plant for $746 mn

The company's target is a 260% jump in output of Nabota to 18 mn bottles per year

Daewoong Pharma to build third botulinum toxin plant for 6 mn
Ji-Hyun Lee 1
2023-05-03 10:59:07 bluesky@hankyung.com
Bio & Pharma

South Korea’s Daewoong Pharmaceutical next year will open a third plant to greatly expand annual output of its botulinum toxin Nabota at a cost of over 100 billion won ($746 million).

The company on Tuesday said the facility will boost production by 13 million units to expand Nabota's business.

Daewoong Pharmaceutical's two factories produce a combined five million bottles of Nabota per year. When the third is completed in the town of Hyangnam in Hwaseong, Gyeonggi Province, production will jump 260% to 18 million per year.

The goal is to start construction in the first half of this year for completion next year.

The new plant will also boost output capacity by optimizing process design to churn out not only conventional formulations but also those of the next generation such as liquid, continuous and microneedles.

Write to Ji-Hyun Lee at bluesky@hankyung.com
#Daewoong Pharmaceutical #botulinum toxin #Nabota #third plant

Daewoong’s Nabota expands into Germany, Austria

Daewoong’s Nabota expands into Germany, Austria

South Korean drugmaker Daewoong Pharmaceutical Co. said on Tuesday it had launched its botulinum toxin product Nabota in Germany and Austria through its overseas partner Evolus Inc., a US performance beauty company.This is the second European launch for Nabota, which is sold under the brand name Nuc

Korean court rules Daewoong poached Medytox’s botox strain

Korean court rules Daewoong poached Medytox’s botox strain

Korean botox maker Medytox A South Korean court on Friday ruled in favor of Medytox Inc. in a civil lawsuit against its crosstown rival Daewoong Pharmaceutical Co. over the source of its botulinum toxin, more commonly known as botox.The Seoul Central District Court accepted Medytox’s clai

Daewoong Pharma wins permission from Singapore for Nabota

Daewoong Pharma wins permission from Singapore for Nabota

Daewoong Phamaceutical's Nabota South Korea's drug development company Daewoong Pharmaceutical said on Thursday that it received on Jan. 20 product approval for its botulinum toxin formulation Nabota (overseas brand name: Nuceiva) from Singapore authorities.The item that received approval this

Daewoong Pharma's botulinum toxin Nabota proves long-lasting effect

Daewoong Pharma's botulinum toxin Nabota proves long-lasting effect

Daewoong Pharma's Nabota (US brand name: Jeuveau) Daewoong Pharmaceutical said on Friday that a high-dose administration of botulinum toxin Nabota (US brand name: Jeuveau) to patients with frown wrinkles showed a six-month long-lasting effect as a result of an interim analysis of a phase 2 clin
(* comment hide *}